These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22228792)

  • 1. Development of immunotoxicity testing strategies for immunomodulatory drugs.
    Kawabata TT; Evans EW
    Toxicol Pathol; 2012; 40(2):288-93. PubMed ID: 22228792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: autonomous or synergistic methods to predict immunotoxicity?
    Spanhaak S
    Exp Toxicol Pathol; 2006 Jul; 57(5-6):373-6. PubMed ID: 16723215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for developmental immunotoxicity guidance and an update on ICH S8.
    Hastings KL
    J Immunotoxicol; 2005 Oct; 2(4):217-20. PubMed ID: 18958677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.
    Collinge M; Burns-Naas LA; Chellman GJ; Kawabata TT; Komocsar WJ; Piccotti JR; Shenton J; Wierda D
    J Immunotoxicol; 2012; 9(2):210-30. PubMed ID: 22428536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects of immunotoxicology.
    Schulte A; Ruehl-Fehlert C
    Exp Toxicol Pathol; 2006 Jul; 57(5-6):385-9. PubMed ID: 16713214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxicity testing in nonhuman primates.
    Grote-Wessels S; Frings W; Smith CA; Weinbauer GF
    Methods Mol Biol; 2010; 598():341-59. PubMed ID: 19967524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxicity testing guidance; availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 May; 64(87):24408-9. PubMed ID: 10558489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of histopathology in the identification of immunotoxicity.
    Haley PJ
    J Immunotoxicol; 2005 Oct; 2(4):181-3. PubMed ID: 18958671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Jun; 77(110):33748-9. PubMed ID: 22675782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
    Giannakou C; Park MVDZ; Bosselaers IEM; de Jong WH; van der Laan JW; van Loveren H; Vandebriel RJ; Geertsma RE
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1633. PubMed ID: 32266791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
    Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
    J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and burning issues in immunotoxicity testing of drugs.
    van der Laan JW; van Loveren H
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):435-40. PubMed ID: 15982690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.
    Danilenko DM; Wang H
    Toxicol Pathol; 2012; 40(2):272-87. PubMed ID: 22222884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Conference on Harmonisation; evaluation of stability data; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jun; 69(110):32010-1. PubMed ID: 15185712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Mar; 75(44):10487-8. PubMed ID: 20383918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; guidance on the duration of chronic toxicity testing in animals (rodent and nonrodent toxicity testing); availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Jun; 64(122):34259-60. PubMed ID: 12356093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.